COMMUNIQUÉS West-GlobeNewswire

Total number of shares and voting rights in Zealand Pharma as of December 31, 2025
31/12/2025
Company announcement – No. 27 / 2025 Total number of shares and voting rights in Zealand Pharma as of December 31, 2025 Copenhagen, Denmark, December 31, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) ( [...]
Valneva et le Serum Institute of India annoncent la fin de leur accord de licence pour le vaccin contre le chikungunya
31/12/2025
Saint-Herblain (France), Pune (Inde) , le 31 décembre 2025 – Valneva SE (« Valneva » ou « la Société »), société spécialisée dans les vaccins, et le Serum Institute of India (SII), société du groupe Cyrus Poonawalla, [...]
Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
31/12/2025
Saint-Herblain (France), Pune, (India), December 31, 2025 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company today announced that [...]
AtaiBeckley Completes Redomiciliation to the United States
31/12/2025
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, [...]
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/12/2025
CLEVELAND, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new executive and non-executive employees who joined the Company. The equity awards [...]
Profusa Bolsters European Commercial Network with New French Distributor, MedSell
31/12/2025
MedSell commercializes Lumee™ Oxygen tissue monitoring in France, building upon distributor partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia, to now reach approximately [...]
Hydreight Technologies Enters the At-Home STI Testing Market With Exclusive Distribution and 50,000 Pre-Orders
31/12/2025
VANCOUVER, British Columbia, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”), a digital health platform enabling on-demand care, pharmacy fulfillment, and enterprise [...]
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
31/12/2025
TARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a [...]
Novo Nordisk A/S: China’s Supreme People’s Court delivers a positive ruling on the semaglutide compound patent
31/12/2025
Bagsværd, Denmark, 31 December 2025 – Today, the Supreme People’s Court in China made a positive decision concerning the intellectual property rights relating to the semaglutide compound patent. Novo Nordisk is pleased [...]
ICU Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
31/12/2025
SAN CLEMENTE, Calif., Dec. 31, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will [...]
FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis
31/12/2025
HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
Intelligent Bio Solutions Announces New Manufacturing Partnership to Strengthen Global Production Capability and Increase Margins
31/12/2025
Partnership with Syrma Johari Medtech, a globally recognized medical device engineering and manufacturing organization, expands INBS’ global manufacturing capacity, strengthens supply-chain resilience, and supports an [...]
Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement
31/12/2025
Vancouver, Canada, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel [...]
BioNTX Marks the Close of the First Quarter of the 21st Century with Growth, Workforce Momentum, and Innovation Leadership
31/12/2025
IRVING, Texas, Dec. 31, 2025 (GLOBE NEWSWIRE) -- As 2025 ends, BioNTX reflects on a year—and the close of the first quarter of the 21st century—defined by accelerated growth, expanded engagement, and strategic [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
31/12/2025
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 31 December 2025 at 13.00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
31/12/2025
New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of [...]
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
31/12/2025
FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a [...]
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
31/12/2025
BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026. BioAtla to retain 65% [...]
SAFE : Assemblée Générale - Approbation de l’ensemble des résolutions
31/12/2025
SAFE Assemblée Générale du 26 décembre 2025 Approbation de l’ensemble des résolutions Fleurieux-sur-l’Arbresle - France - le 31 décembre 2025 à 8h . L’assemblée générale des actionnaires de Safe réunie le 26 décembre [...]

Pages